Abstract
Crohn’s disease (CD) of the pouch and chronic pouchitis represent the most common long-term complications of total proctocolectomy and ileal pouch anal anastomosis (IPAA) for refractory ulcerative colitis (UC). These conditions are treated with multiple agents, including antibiotics, immunomodulators, and biologics. Among the latter, ustekinumab is approved for both CD and UC. We performed a systematic review to evaluate the efficacy of this anti-IL12/23 in CD of the pouch and chronic refractory pouchitis. Pubmed, Embase, Ovid, and the Cochrane Controlled Trials Register were searched to identify studies published until August 2020 investigating the use of ustekinumab for these conditions. Eighty-six eligible patients with IPAA—51 with CD of the pouch, 35 with chronic pouchitis—were identified from 2 retrospective studies and 5 case reports. Reported clinical response to ustekinumab was 63 and 85% in chronic pouchitis and CD of the pouch after 4–12 and 4–16 weeks, respectively. Clinical remission was reported in 10% of patients with chronic pouchitis and 27% of patients with CD of the pouch after 8–52 and 4–52 weeks of treatment, respectively. Endoscopic response was reported in 60% and 67% of patients with chronic pouchitis and CD of the pouch after 24–32 and 8–24 weeks of treatment respectively. Small sample sizes and large heterogeneity of therapy protocols/outcome definitions were significant studies limitations. In conclusion, there is a limited and inconclusive body of evidence suggesting that ustekinumab may be a therapeutic option for patients with chronic pouchitis and CD of the pouch refractory to other therapies.
Similar content being viewed by others
Change history
21 June 2021
The first name and the family name of the fourth author, Salvatore F. Vadalà di Prampero has been corrected. The author name was published with the first name as ‘Salvatore F. Vadalà’ and the family name as ‘di Prampero’. The corrected first name is ‘Salvatore F.’ and the family name is ‘Vadalà di Prampero’.
References
Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: when? how? Best Pract Res Clin Gastroenterol. 2018;32–33:71–78.
Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J. 1978;2:85–88.
Carcamo L, Miranda P, Zúñiga A et al. Ileal pouch–anal anastomosis in ulcerative colitis: outcomes, functional results, and quality of life in patients with more than 10-year follow-up. Int J Colorectal Dis. 2020;35:747–753.
Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2019;5:CD001176.
Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing, and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg. 1996;131:497–502.
Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg. 1990;211:622–629.
Magro F, Gionchetti P, Eliakim R et al. Third european evidence-based consensus on diagnosis and management of ulcerative colitis part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo- anal pouch disorders. J Crohns Colitis. 2017;11:649–670.
Kayal M, Plietz M, Radcliffe M et al. Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. Aliment Pharmacol Ther. 2019;50:1189–1194.
Mark-Christensen A, Brandsborg S, Laurberg S. Primary fecal diversion and bowel dysfunction in restorative proctocolectomy for ulcerative colitis: a nationwide cross-sectional study. Int J Colorectal Dis. 2018;33:223–229.
Lightner AL, Pemberton JH, Loftus EJ. Crohnʼs disease of the ileoanal pouch. Inflamm Bowel Dis. 2016;22:1502–1508.
Grucela AL, Bauer JJ, Gorfine SR, Chessin DB. Outcome and long-term function of restorative proctocolectomy for Crohn’s disease: comparison to patients with ulcerative colitis. Colorectal Dis. 2011;13:426–430.
Shen B, Patel S, Lian L. Natural history of Crohn’s disease in patients who underwent intentional restorative proctocolectomy with ileal pouch-anal anastomosis. Aliment Pharmacol Ther. 2010;31:745–753.
James SD, Wise PE, Zuluaga-Toro T, Schwartz DA, Washington MK, Shi C. Identification of pathologic features associated with “ulcerative colitis-like” Crohn’s disease. World J Gastroenterol. 2014;20:13139–13145.
Gionchetti P, Calafiore A, Riso D et al. The role of antibiotics and probiotics in pouchitis. Ann Gastroenterol. 2012;25:100–105.
Shen B, Achkar JP, Lashner BA et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301–305.
Suzuki H, Ogawa H, Shibata C et al. The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis. Dis Colon Rectum. 2012;55:330–336.
Segal JP, Ding NS, Worley G et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Aliment Pharmacol Ther. 2017;45:581–592.
Shiraki M, Yamamoto T. Efficacy of biologic therapy in patients with chronic pouchitis. Int J Colorectal Dis. 2013;28:885.
Gregory M, Weaver KN, Hoversten P et al. Efficacy of vedolizumab for refractory pouchitis of the ileo-anal pouch: results from a multicenter US cohort. Inflamm Bowel Dis. 2019;25:1569–1576.
Singh A, Khan F, Lopez R, Shen B, Philpott J. Vedolizumab for chronic antibiotic-refractory pouchitis. Gastroenterol Rep (Oxf). 2019;7:121–126.
Selvig D, Piceno Y, Terdiman J et al. Fecal microbiota transplantation in pouchitis: clinical, endoscopic, histologic, and microbiota results from a pilot study. Dig Dis Sci. 2020;65:1099–1106.
Bamias G, Rivera-Nieves J, Mantzaris GJ. Efficacy of IL12/23 blockade expands our therapeutic targets and challenges the old dogma in ulcerative colitis. Gastroenterology. 2020;158:1836–1837.
Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
Sulz MC, Burri E, Michetti P et al. Treatment algorithms for Crohn’s disease. Digestion. 2020;101:43–57.
Weaver KN, Gregory M, Syal G et al. Ustekinumab Is effective for the treatment of Crohn’s disease of the pouch in a multicenter cohort. Inflamm Bowel Dis. 2019;25:767–774.
Ollech JE, Rubin DT, Glick L et al. Ustekinumab is effective for the treatment of chronic antibiotic-refractory pouchitis. Dig Dis Sci. 2019;64:3596–3601.
Tran-Minh M-L, Allez M, Gornet J-M. Successful treatment with ustekinumab for chronic refractory pouchitis. J Crohns Colitis. 2017;11:1156–1156.
Teich N, Stallmach A. Effective use of ustekinumab for prepouch ileitis without improvement of concomitant pouchitis. Tech Coloproctol. 2018;22:251–252.
Peter J, Zeitz J, Stallmach A. Ustekinumab rescue therapy in a patient with chronic refractory pouchitis. J Crohns Colitis. 2018;12:1008–1009.
Singh A, Ghouri Y, Shen B. Ustekinumab as an induction agent for Crohn’s disease of the pouch. Inflamm Bowel Dis. 2018;24:e12-13.
Khan F, Shen B. Ustekinumab treatment in Crohn’s disease of barnett continent intestinal reservoir. Inflamm Bowel Dis. 2018;24:e2-3.
Goldstein NS, Sanford WW, Bodzin JH. Crohn’s-like complications in patients with ulcerative colitis after total proctocolectomy and ileal pouch-anal anastomosis. Am J Surg Pathol. 1997;21:1343–1353.
Huguet M, Pereira B, Goutte M et al. Systematic review with meta-analysis: anti-TNF therapy in refractory pouchitis and Crohn’s disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis. Inflamm Bowel Dis. 2018;24:261–268.
Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214.
Harris RJ, McDonnell M, Young D et al. Early real-world effectiveness of ustekinumab for Crohn’s disease. Frontline Gastroenterol. 2020;11:111–116.
Heuschen UA, Allemeyer EH, Hinz U et al. Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up. Dis Colon Rectum. 2002;45:776–786.
Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology. 2017;152:362–373.
Wright EK, Kamm MA, De Cruz P et al. Anti-TNF therapeutic drug monitoring in postoperative Crohn’s disease. J Crohns Colitis. 2018;12:653–661.
Singh S, Proudfoot J, Xu R, Sandborn WJ. Obesity and response to infliximab in patients with inflammatory bowel diseases: pooled analysis of individual participant data from clinical Trials. Am J Gastroenterol. 2018;113:883–889.
Holt DQ, Moore GT, Strauss BJG, Hamilton AL, De Cruz P, Kamm MA. Visceral adiposity predicts post-operative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2017;45:1255–1264.
Zezos P, Saibil F. Inflammatory pouch disease: the spectrum of pouchitis. World J Gastroenterol. 2015;21:8739–8752.
Rubio MG, Amo-Mensah K, Gray JM et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2019;10:54–63.
D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151–161.
Acknowledgment
We would like to thank Dr. Barnes [25], Dr. Rubin [26], Dr. Teich [28], Dr. Peter [29], and Dr. Singh [30] for sharing additional unpublished data with us as available.
Funding
This work was not supported by any grants. No financial arrangements to disclose.
Author information
Authors and Affiliations
Contributions
DS has received consulting fees from Abbott/AbbVie, Schering-Plough, MSD, Janssen Research & Development, LLC., Centocor Inc., TechLab, Hoffmann-LaRoche, Giuliani, Schering-Plough, and Ferring; research grants from AbbVie, Janssen Research & Development, LLC, Schering-Plough, TechLab, Centocor, Takeda and serves in the Speakers Bureau of AbbVie and the National Faculty of Janssen.
Corresponding author
Ethics declarations
Conflicts of interest
The other authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The first name and the family name of the fourth author, Salvatore F. Vadalà di Prampero has been corrected. The author name was published with the first name as ‘Salvatore F. Vadalà’ and the family name as ‘di Prampero’. The corrected first name is ‘Salvatore F.’ and the family name is ‘Vadalà di Prampero’.
Rights and permissions
About this article
Cite this article
Rocchi, C., Soliman, Y.Y., Massidda, M. et al. Is Ustekinumab Effective in Refractory Crohn’s Disease of the Pouch and Chronic Pouchitis? A Systematic Review. Dig Dis Sci 67, 1948–1955 (2022). https://doi.org/10.1007/s10620-021-07002-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-021-07002-5